

Correction: *Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort*

Cho BC, Daste A, Ravaud A, *et al.* Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. *J Immunother Cancer* 2020;8:e000664. doi: 10.1136/jitc-2020-000664

This article has been corrected since it was published. The disease control rate in the abstract, efficacy results and Table 2 has been updated from 25% to 34%. Additionally, the number of responses by immune phenotype quoted in the text was updated to match the data shown in Figure 3.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;8:e000664corr1. doi:10.1136/jitc-2020-000664corr1

